News Release

New class of drug kills lymphoma cells

Experimental compound designed by Weill Cornell researchers being developed for clinical testing

Peer-Reviewed Publication

NewYork-Presbyterian

NEW YORK (April 13, 2010) -- Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma.

Findings published in today's issue of Cancer Cell show that an experimental compound designed by a team of researchers from Weill Cornell Medical College, the University of Maryland and the Ontario Cancer Center at the University of Toronto may effectively block the cancer-causing actions of BCL6 by attaching to a critical "hot spot" on its surface, thus killing off the cancer cells.

"BCL6 mediates its cancer-causing actions by attaching to other proteins," explains Dr. Ari Melnick, associate professor of medicine from the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell Medical College. "Traditionally protein-protein interactions have been viewed as being too difficult to block with small-molecule drugs."

Accordingly, by observing the atomic scale structure of BCL6 attached to its partner proteins, Dr. Melnick and colleagues identified a critical "hot spot" that appeared to be amenable to designing a drug. Dr. Alexander Mackerell, from the University of Maryland, then used computational modeling to identify chemical structures that could attack this hot spot.

"We tested the ability of a large number of these chemicals to bind and block BCL6," said Dr. Melnick, "and then Dr. Gilbert Privé, from the University of Toronto, performed nuclear magnetic resonance and X-ray crystallography studies to show that a specific BCL6 inhibitor compound hit exactly in the center of the predicted hot spot. Our results show that given the right scientific approach it is quite possible to design drugs against key protein regulatory factors like BCL6."

Dr. Melnick's group showed that the BCL6 inhibitor was specific for BCL6 and did not block other master regulators, and that the experimental drug could powerfully kill DLBCL cells derived from human patients with this disease. Remarkably, the compound was completely non-toxic to animals, and could powerfully suppress and improve survival in animal models.

"This means that if given as a therapeutic agent, the compound would be unlikely to have ill-effects on healthy normal cells, and therefore would not be expected to have significant side effects," explains Dr. Melnick. "Since emerging data implicates BCL6 in other tumor types in addition to non-Hodgkin's lymphoma, it is possible that BCL6-targeted therapy could benefit many other cancer patients."

Dr. Melnick is among the physician-scientists supported by the Leukemia and Lymphoma Society's (LLS) Scholar Award Program. Since 2005, LLS has funded research in Dr. Melnick's laboratory, much of which has been focused on developing better treatments for patients with B-cell lymphomas. Dr. Melnick is also the leader of a Samuel Waxman Cancer Research Foundation Program Grant, which directly supported the effort to design small molecules for the BCL6 hot spot by the Melnick, Privé and Mackerell research team. The results of Dr. Melnick's work in this area led the LLS to form a drug discovery partnership with Forma Therapeutics to improve these drugs so they can be used in human clinical trials for hematological malignant cancers.

###

The Raymond and Beverly Sackler Center for Biomedical and Physical Sciences

The Raymond and Beverly Sackler Center for Biomedical and Physical Sciences of Weill Cornell Medical College brings together a multidisciplinary team of scientists for the purpose of catalyzing major advances in medicine. By harnessing the combined power of experimental approaches rooted in the physical and biological sciences, Sackler Center investigators can best accelerate the pace of discovery and translate these findings for the benefit of patients with various medical conditions including but not limited to cancer.

Weill Cornell Medical College

Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston, making Weill Cornell one of only two medical colleges in the country affiliated with two U.S.News & World Report Honor Roll hospitals. For more information, visit www.med.cornell.edu.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.